Alendronate Sodium Tablet
Product Images NDC 68071-3340

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Alendronate Sodium (NDC 68071-3340). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (549c6214 D56a 48e7 Ac76 725908eea67b 01)

Chemical structure of Alendronate sodium dihydrate, showing the molecular arrangement of atoms including phosphonate groups and an amine side chain.*

FDA Label Image

2 (549c6214 D56a 48e7 Ac76 725908eea67b 02)

A line graph depicting the cumulative incidence of hip fractures over a 36-month period in a study comparing placebo and Alendronate Sodium. The x-axis shows time in months, and the y-axis shows cumulative incidence percentage. Two lines represent placebo (dashed line) and Alendronate Sodium (solid line), showing a lower incidence for Alendronate Sodium over time.*

FDA Label Image

3 (549c6214 D56a 48e7 Ac76 725908eea67b 03)

A bar chart titled 'Osteoporosis Treatment Studies in Postmenopausal Women' showing mean percentage increase in bone mineral density (BMD) relative to placebo after three years of Alendronate Sodium 10 mg/day. It compares results between U.S. and multinational groups for lumbar spine, femoral neck, and trochanter regions.*

FDA Label Image

4 (549c6214 D56a 48e7 Ac76 725908eea67b 04)

This image contains two line graphs displaying osteoporosis treatment studies in postmenopausal women. The graphs show the time course of the effect of Alendronate Sodium 10 mg/day versus placebo on lumbar spine bone mineral density (BMD) percent change from baseline over 36 months. The first graph is labeled US Study and the second is labeled Multinational Study, both plotting BMD percent change on the y-axis against time in months on the x-axis.*

FDA Label Image

5 (549c6214 D56a 48e7 Ac76 725908eea67b 05)

A pair of bar charts titled 'Osteoporosis Prevention Studies in Postmenopausal Women' showing percent changes in bone mineral density (BMD) from baseline at 2 years and 3 years. The charts compare Alendronate Sodium 5 mg/day and placebo groups across lumbar spine, femoral neck, trochanter, and total body sites. Alendronate shows positive BMD changes, while placebo generally shows negative changes in these areas.*

FDA Label Image

6 (549c6214 D56a 48e7 Ac76 725908eea67b 06)

A bar chart titled 'Studies in Glucocorticoid - Treated Patients Increase in BMD Alendronate Sodium 5 mg/day at One Year' comparing mean percentage increase in bone mineral density (BMD) at the lumbar spine, femoral neck, and trochanter. The chart shows two groups, U.S. and Multinational, with error bars indicating standard error.*

FDA Label Image

7 (549c6214 D56a 48e7 Ac76 725908eea67b 07)

A line graph depicting the effect on serum alkaline phosphatase levels over 6 months in patients with Paget's disease of bone. It compares Alendronate Sodium 40 mg/day (two studies), Etidronate 400 mg/day, and placebo, showing mean percentage change from baseline with standard error. The graph includes sample sizes (N) for each group.*

FDA Label Image

68071 3340 4

Label for Alendronate Sodium 70 mg tablets by NuCare Pharmaceuticals, Inc. The label includes the NDC 68071-3340-4, indicates a package size of 4 tablets, and notes prescription use only. It shows manufacturing by Cipla Ltd., Verna Goa, India, and storage instructions of 59-86°F. Additional details include a barcode, usage instructions, a warning to keep out of reach of children, and contact information for reporting side effects.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.